PDCD1 and cancer: Immunotherapy is one of the most important breakthroughs in cancer treatment, and, compared with standard therapies, immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) have been found to significantly prolong overall survival (OS) in patients with many different tumor types [1, 2].